What is King Pharmaceuticals's all other lines — year 9?

King Pharmaceuticals (KG) reported all other lines — year 9 of -0.4% in Q4 2025.

What does all other lines — year 9 mean?

This metric reflects the financial results of non-core business segments and miscellaneous operations for the ninth fiscal year. It provides a consolidated view of secondary activities that are not classified under the company's primary reporting segments. Investors monitor this to gauge the performance and strategic relevance of the company's diversified business lines.

King Pharmaceuticals KG All other lines — Year 9

Other product segments

European Hospital Liability

4.9%—

General Liability

3.8%—

Commercial Auto Liability

1.6%—

International

-0.7%—

Similar metrics at other companies

GLREFinancial — Year 9

0.2%—

SPNTOther — Year 9

0%—

ACGLMulti-line and other specialty — Year Nine

1.1%+0.3pp

SPNTOther — Year 10

0%—

SKWDMulti-line Solutions — Year 9

1.3%-0.7pp

GLREMultiline — Year 9

0.4%—

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearNine.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's all other lines — year 9.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's all other lines — year 9?: King Pharmaceuticals (KG) reported all other lines — year 9 of -0.4% in Q4 2025.
What does all other lines — year 9 mean?: This metric reflects the financial results of non-core business segments and miscellaneous operations for the ninth fiscal year. It provides a consolidated view of secondary activities that are not classified under the company's primary reporting segments. Investors monitor this to gauge the performance and strategic relevance of the company's diversified business lines.